FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979430111> ?p ?o ?g. }

• W2979430111 abstract "Abstract Abstract 3402 Poster Board III-290 Clofarabine (Clo) is a second-generation purine nucleoside antimetabolite, which unlike other purine nucleoside analogues, has a higher resistance to the action of adenosine deaminase and improved affinity for the activating phosphorylating enzyme deoxycytidine kinase, contributing to more potent activity against neoplastic cells. Recently, Clo was shown to have significant single agent activity in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL), but resulted in prolonged myelosuppression (Blum et al. Leuk Lymphoma 2009, 50: 349-56), suggesting that it may be a useful agent in high-dose therapy with stem cell support. We conducted a phase I trial to determine the maximum tolerated dose (MTD) of Clo in combination with high-dose Etoposide and Cyclophosphamide followed by autologous stem cell rescue in patients with relapsed or refractory NHL. Patients received Clo at 30-70 mg/m2/day on days -6 to -2 in successive cohorts, in combination with Etoposide 60 mg/kg day -8, and Cyclophosphamide 100 mg/kg days -6. G-CSF-mobilized autologous PBSC were infused on day 0. Patients were eligible if aged 18-70 years, had primary refractory or relapsed and refractory diffuse large cell lymphoma (DLCL), mantle cell lymphoma (MCL), or follicular lymphoma (FL), had Karnofsky performance status ≥70%, and adequate organ function. Toxicity was scored using the Common Terminology Criteria for Adverse events, version 3.0. Dose limiting toxicity (DLT) was defined as any grade 3-4 non-hematologic toxicity that did not resolve to grade 2 or less by day 30. Fifteen patients were treated at 5 Clo dose levels, 30 (n=3), 40 (n=3), 50 (n=3), 60 (n=3), and 70 (n=3) mg/m2/day. Seven males and 8 females of median age 55 (32-67) years, with DLCL (n=8), MCL (n=3), and FL (n=4) were treated. At transplant, NHL was primary refractory (n=2), in first resistant relapse (n=7), and in second or third relapsed (n=6). Median number of lines of treatment failed before transplant was 3 (2-6). Median CD34+ count infused was 1.9 (0.9-3.7) x106/kg. The median time to neutrophils >0.5×109/l was 10 (9-13) days, and to platelets >20×109/l was 16 (10-33) days. Only 1 patient treated at the 30 mg/m2 dose level and infused with 0.9×106 CD34+cell/kg failed to achieve platelets > 20×109/l. No DLT was observed. Grades 3-4 non-hematological toxicity included neutropenic fever (n=9), vomiting (n=2), diarrhea (n=2), mucositis (n=1), and hemorrhagic cystitis (n=1); all toxicities resolved by day 30. Only grade 1-2 elevation of transaminases (AST/ALT) occurred; 2 of 3 patients at 30 mg/m2, 3 of 3 at 40 mg/m2, 2 of 3 at 50 mg/m2, 1 of 3 at 60 mg/m2, 2 of 3 patients at 70 mg/m2 dose levels. AST/ALT peaked at day -1 to +1 and returned to baseline in all patients by day 10, with no long-term sequelae. There was no correlation between clofarabine dose and peak AST/ALT. No treatment related deaths occurred. Fourteen of the 15 patients (93%) achieved a response; complete response (CR) or CR unconfirmed (CRu) in 12, and partial response in 2 patients. Only patient treated at the 30 mg/m2 dose level failed to respond. Four patients had progression of disease or relapse at 30 to 135 days after transplant. With a median follow-up of 199 days to date, the 1-year progression-free survival is 72% ± 12%, and the 1-year overall survival is 93% ± 6%. Clo at doses as high as 70 mg/m2/day x 5 days in combination with high-dose Etoposide (60 mg/kg) and Cyclophosphamide (100 mg/kg) are well tolerated, and showed promising efficacy in very-high risk NHL patients. The MTD has not been reached. We recommend the dose of Clo 70 mg/m2/day x 5 days in combination with high-dose Etoposide and Cyclophosphamide for Phase II testing as a preparative regimen in NHL patients undergoing autologous PBSC transplantation. Disclosures: Off Label Use: Clofarabine for high-dose chemotherapy and autologous stem cell transplantation." @default.
• W2979430111 created "2019-10-18" @default.
• W2979430111 creator A5006178388 @default.
• W2979430111 creator A5016032533 @default.
• W2979430111 creator A5021008652 @default.
• W2979430111 creator A5031102780 @default.
• W2979430111 creator A5047486042 @default.
• W2979430111 creator A5053917846 @default.
• W2979430111 creator A5056697792 @default.
• W2979430111 creator A5076249181 @default.
• W2979430111 date "2009-11-20" @default.
• W2979430111 modified "2023-10-01" @default.
• W2979430111 title "A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide: A Novel Preparative Regimen Prior to Autologous Peripheral Blood Stem Cell (PBSC) Transplantation in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma." @default.
• W2979430111 doi "https://doi.org/10.1182/blood.v114.22.3402.3402" @default.
• W2979430111 hasPublicationYear "2009" @default.
• W2979430111 type Work @default.
• W2979430111 sameAs 2979430111 @default.
• W2979430111 citedByCount "0" @default.
• W2979430111 crossrefType "journal-article" @default.
• W2979430111 hasAuthorship W2979430111A5006178388 @default.
• W2979430111 hasAuthorship W2979430111A5016032533 @default.
• W2979430111 hasAuthorship W2979430111A5021008652 @default.
• W2979430111 hasAuthorship W2979430111A5031102780 @default.
• W2979430111 hasAuthorship W2979430111A5047486042 @default.
• W2979430111 hasAuthorship W2979430111A5053917846 @default.
• W2979430111 hasAuthorship W2979430111A5056697792 @default.
• W2979430111 hasAuthorship W2979430111A5076249181 @default.
• W2979430111 hasConcept C126322002 @default.
• W2979430111 hasConcept C141071460 @default.
• W2979430111 hasConcept C143998085 @default.
• W2979430111 hasConcept C2776694085 @default.
• W2979430111 hasConcept C2777058707 @default.
• W2979430111 hasConcept C2777198975 @default.
• W2979430111 hasConcept C2777525834 @default.
• W2979430111 hasConcept C2778041864 @default.
• W2979430111 hasConcept C2778119113 @default.
• W2979430111 hasConcept C2779338263 @default.
• W2979430111 hasConcept C2911091166 @default.
• W2979430111 hasConcept C71924100 @default.
• W2979430111 hasConcept C90924648 @default.
• W2979430111 hasConcept C98274493 @default.
• W2979430111 hasConceptScore W2979430111C126322002 @default.
• W2979430111 hasConceptScore W2979430111C141071460 @default.
• W2979430111 hasConceptScore W2979430111C143998085 @default.
• W2979430111 hasConceptScore W2979430111C2776694085 @default.
• W2979430111 hasConceptScore W2979430111C2777058707 @default.
• W2979430111 hasConceptScore W2979430111C2777198975 @default.
• W2979430111 hasConceptScore W2979430111C2777525834 @default.
• W2979430111 hasConceptScore W2979430111C2778041864 @default.
• W2979430111 hasConceptScore W2979430111C2778119113 @default.
• W2979430111 hasConceptScore W2979430111C2779338263 @default.
• W2979430111 hasConceptScore W2979430111C2911091166 @default.
• W2979430111 hasConceptScore W2979430111C71924100 @default.
• W2979430111 hasConceptScore W2979430111C90924648 @default.
• W2979430111 hasConceptScore W2979430111C98274493 @default.
• W2979430111 hasLocation W29794301111 @default.
• W2979430111 hasOpenAccess W2979430111 @default.
• W2979430111 hasPrimaryLocation W29794301111 @default.
• W2979430111 hasRelatedWork W1974980935 @default.
• W2979430111 hasRelatedWork W1978895378 @default.
• W2979430111 hasRelatedWork W1991664636 @default.
• W2979430111 hasRelatedWork W2035343938 @default.
• W2979430111 hasRelatedWork W2043637526 @default.
• W2979430111 hasRelatedWork W2063906917 @default.
• W2979430111 hasRelatedWork W2121830832 @default.
• W2979430111 hasRelatedWork W2240952869 @default.
• W2979430111 hasRelatedWork W2291962142 @default.
• W2979430111 hasRelatedWork W2363505139 @default.
• W2979430111 hasRelatedWork W2374179136 @default.
• W2979430111 hasRelatedWork W2393732692 @default.
• W2979430111 hasRelatedWork W2417813554 @default.
• W2979430111 hasRelatedWork W2467189446 @default.
• W2979430111 hasRelatedWork W2558094369 @default.
• W2979430111 hasRelatedWork W2558156821 @default.
• W2979430111 hasRelatedWork W2565568893 @default.
• W2979430111 hasRelatedWork W2581508889 @default.
• W2979430111 hasRelatedWork W2586422565 @default.
• W2979430111 hasRelatedWork W2587029748 @default.
• W2979430111 isParatext "false" @default.
• W2979430111 isRetracted "false" @default.
• W2979430111 magId "2979430111" @default.
• W2979430111 workType "article" @default.